Results 71 to 80 of about 75,323 (218)

Impact of the Specific Mutation in KRAS Codon 12 Mutated Tumors on Treatment Efficacy in Patients with Metastatic Colorectal Cancer Receiving Cetuximab-Based First-Line Therapy: A Pooled Analysis of Three Trials [PDF]

, 2012
Purpose: This study investigated the impact of specific mutations in codon 12 of the Kirsten-ras (KRAS) gene on treatment efficacy in patients with metastatic colorectal cancer (mCRC).
Allegra CJ, Amado RG, Andreas Jung, Andreyev HJ, Bazan V, Bokemeyer C, Bos JL, Boughdady IS, Cappuzzo F, Cerottini JP, Christoph C. Zielinski, De Roock W, Dominik P. Modest, Douillard JY, Finkelstein SD, Frattini M, Galina Kurteva, Heinemann V, Janja Ocvirk, Jens Neumann, Jonker DJ, Karapetis CS, Khambata-Ford S, Khosravi-Far R, Lièvre A, Maughan TS, Moosmann N, Neumann J, Ocvirk J, Regina Knittelfelder, Roth AD, Ruediger P. Laubender, Samowitz WS, Scheffzek K, Sebastian Stintzing, Thomas Brodowicz, Thomas Kirchner, Tournigand C, Tveit K, Van Cutsem E, Volker Heinemann, Zsuzsanna Papai   +41 more
core   +1 more source

Main factors associated with variability in the assessment of the objective response rate. A re‐analysis of the PHEREXA phase 3 clinical trial

British Journal of Clinical Pharmacology, EarlyView.
Abstract Aim Local investigators (LIs) overestimate the objective response rate (ORR) in comparison to Blinded Independent Central Reviewers (BICR) in oncology. In this study, we re‐analysed data obtained in the PHEREXA trial (NCT01026142) with the following aims: i) to confirm at the single‐patient level the discrepancy observed by analysing ...
Gennaro Daniele, Tommaso Giovagnoli, Pierluigi Navarra, Cinzia Dello Russo   +3 more
wiley   +1 more source

Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation [PDF]

, 2003
Objectives: To evaluate the clinical and costeffectiveness of capecitabine and tegafur with uracil (UFT/LV) as first-line treatments for patients with metastatic colorectal cancer, as compared with 5- fluorouracil/folinic acid (5-FU/FA) regimens.
Brewer, N., Cowan, J., Kaltenthaler, E., Ward, S.   +3 more
core   +1 more source

Consistency and clarity of pharmacogenomic guidance in UK medicine patient information leaflets: A cross‐sectional analysis

British Journal of Clinical Pharmacology, EarlyView.
Pharmacogenomic (PGx) information has the potential to support the safe and effective use of medicines, yet there is uncertainty about how this information can be best communicated to patients. Summaries of product characteristics (SmPCs) and patient information leaflets (PILs) for all UK‐approved medicines with strong evidence supporting a PGx ...
Parth Narlawar, Chloe Ratcliffe, Videha Sharma, William G. Newman, Munir Pirmohamed, John McDermott   +5 more
wiley   +1 more source

Efficacy of adjuvant capecitabine in triple-negative breast cancer with residual disease after neoadjuvant therapy: a real-world study

Breast
Purpose: To determine the beneficiaries of capecitabine in patients with triple-negative breast cancer (TNBC) who failed to achieve pathological complete response (pCR) by analyzing the efficacy of the drug in different HER2 statuses and TNM stages ...
Youzhao Ma, Mingda Zhu, Jingyang Zhang, Dechuang Jiao, Yangyang Hou, Xiuchun Chen, Zhenzhen Liu   +6 more
doaj   +1 more source

First efficacy results of capecitabine with anthracycline- and taxane-based adjuvant therapy in high-risk early breast cancer: a meta-analysis.

PLoS ONE, 2012
BackgroundCapecitabine is effective and indicated for the salvage treatment of metastatic breast cancer. Therefore, it is essential to evaluate the efficacy of capecitabine in the adjuvant setting.
Yiwei Jiang, Wenjin Yin, Liheng Zhou, Tingting Yan, Qiong Zhou, Yueyao Du, Zhenzhou Shen, Zhimin Shao, Jinsong Lu   +8 more
doaj   +1 more source

Molecular–clinical characteristics and treatment outcomes in 163 metastatic colorectal neuroendocrine carcinomas with a comparison to colorectal adenocarcinomas

International Journal of Cancer, EarlyView.
What's New? Colorectal neuroendocrine carcinoma (CR‐NEC) is a rare digestive neuroendocrine neoplasm that frequently exhibits an adenocarcinoma component. Nonetheless, the underlying biology of CR‐NEC remains poorly understood. This study examined molecular and clinical features and palliative chemotherapy outcomes of metastatic CR‐NEC, with comparison
Siren Morken, Seppo W. Langer, Geir Olav Hjortland, Anna Sundlöv, Eva Hofsli, Morten Ladekarl, Elizaveta Tabaksblat, Lene Weber Vestermark, Johanna Svensson, Ulrich Knigge, Luís Nunes, Bengt Glimelius, Per Pfeiffer, Kristine Aasebø, Jörg Assmus, Erik Vassella, Inger Marie Bowitz Lothe, Anne Couvelard, Aurel Perren, Stian Knappskog, Halfdan Sorbye   +20 more
wiley   +1 more source

Evaluation of Nanocarrier Targeted Drug Delivery of Capecitabine-PAMAM Dendrimer Complex in a Mice Colorectal Cancer Model

Acta Medica Iranica, 2016
Capecitabine, an effective anticancer drug in colorectal cancer chemotherapy, may create adverse side effects on healthy tissues. In the present study, we first induced colon adenocarcinoma with azoxymethane, a carcinogen agent, and then investigated the
Fatemeh Nabavizadeh, Hafseh Fanaei, Alireza Imani, Jalal Vahedian, Fahimeh Asadi Amoli, Jamal Ghorbi, Hamid Sohanaki, Seyed Mehdi Mohammadi, Ravieh Golchoobian   +8 more
doaj  

Oral capecitabine in gemcitabine-pretreated patients with advanced pancreatic cancer [PDF]

, 2007
Objective: To date, no standard regimen for salvage chemotherapy after gemcitabine (Gem) failure has been defined for patients with advanced pancreatic cancer (PC). Oral capecitabine (Cap) has shown promising activity in first-line chemotherapy trials in
Boeck, Stefan, Bruns, Christiane J., Golf, Alexander, Haas, Michael, Heinemann, Volker, Issels, Rolf-Dieter, Laessig, Dorit, Moosmann, Nicolas, Schulz, Christoph, Wilkowski, Ralf   +9 more
core   +1 more source

Oxaliplatin‐induced neuropathy after total neoadjuvant therapy for rectal cancer: Dose–response relationship and impact on quality of life

International Journal of Cancer, EarlyView.
What's New? Oxaliplatin serves a key role in the treatment of rectal cancer, though it is a significant cause of chemotherapy‐induced peripheral neuropathy. As total neoadjuvant therapy, in which all therapy is given before surgery, has become more common, understanding neuropathy has grown increasingly important. This study examined neuropathy and its
Georg W. Wurschi, Andreas Hinz, Melanie Schneider, Jan‐Niklas Becker, Bernd Frerker, Samuel M. Vorbach, Felix Ehret, Markus Diefenhardt, Fabian Schunn, Maria‐Elena von Gruben, Marcel Büttner, Elgin Hoffmann, Alexander Rühle, Josephine Beier, Simone Ferdinandus, Maike Trommer, Ezgi Ceren Sahin, Julian Hlouschek, Kynann Aninditha, Daphne Schepers von Ohlen, Justus Kaufmann, Alina Depardon, Hai Minh Ha, Christopher Kessler, Adrianna Cieslak, Simon Trommer, Alexander Fabian, Florian Rißner, Maximilian Römer, Klaus Pietschmann   +29 more
wiley   +1 more source